Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | IL1B | P01584 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003828 | 0.85 | GAPDH (0.38) | GAPDHALDH1A1IL1BP2RX7NPC1 | |
| SCHEMBL30003568 | 0.84 | ADK (0.44) | GAPDHALDH1A1 | |
| SCHEMBL25109983 | 0.84 | ADK (0.44) | GAPDHALDH1A1 | |
| SCHEMBL31123702 | 0.78 | ALDH1A1 (0.34) | GAPDHALDH1A1NPC1POLBHTT | |
| SCHEMBL29324914 | 0.76 | POLB (0.42) | ALDH1A1POLBKMT2A | |
| SCHEMBL25109992 | 0.75 | PRMT5 (0.41) | ALDH1A1 | |
| SCHEMBL30003625 | 0.75 | PRMT5 (0.41) | ALDH1A1 | |
| SCHEMBL20557502 | 0.74 | ALDH1A1 (0.45) | ALDH1A1NPC1TSHRKMT2AABCB1 | |
| SCHEMBL29324933 | 0.74 | ALDH1A1 (0.45) | ALDH1A1NPC1TSHRKMT2AABCB1 | |
| SCHEMBL16576324 | 0.74 | ALDH1A1 (0.45) | ALDH1A1NPC1TSHRKMT2AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173026-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220363707-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363707-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | GAPDH 1109/4885ALDH1A1 1380/4885IL1B 4143/4885 |
| US-12173026-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | GAPDH 1109/4885ALDH1A1 1380/4885IL1B 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.